# Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke

Study · id `cardio:ct-nct07730840` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07730840](<https://clinicaltrials.gov/study/NCT07730840>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07730840

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 984 participants.

## Technical summary

Registry record NCT07730840. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-15 (anticipated); primary completion 2029-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 984 participants (planned count; ClinicalTrials.gov record NCT07730840, source copy `cardio:ctgov-nct07730840-2026-10-09`, retrieved 2026-10-26)
- Planned start: 2026-10-15 (anticipated) (ClinicalTrials.gov record NCT07730840, source copy `cardio:ctgov-nct07730840-2026-10-09`, retrieved 2026-10-26)
- Primary completion: 2029-09-30 (anticipated) (ClinicalTrials.gov record NCT07730840, source copy `cardio:ctgov-nct07730840-2026-10-09`, retrieved 2026-10-26)
- Completion: 2029-09-30 (anticipated) (ClinicalTrials.gov record NCT07730840, source copy `cardio:ctgov-nct07730840-2026-10-09`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07730840, source copy `cardio:ctgov-nct07730840-2026-10-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07730840-2026-10-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
- Condition: Ischemic Stroke
- Condition: Transient Ischemic Attack
- Intervention (Drug): Zastaprazan
- Intervention (Drug): Placebo
- Lead sponsor: Asan Medical Center
- Lead sponsor class: OTHER
- Collaborator: Jeil Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Transient ischemic attack (mini-stroke) (`cardio:transient-ischemic-attack`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Asan Medical Center (`cardio:org-asan-medical-center`)
- Registry lists this organization as a collaborator: Jeil Pharmaceutical Co., Ltd. (`cardio:org-jeil-pharmaceutical-co-ltd`)

## Provenance

Content hash: 8b48e0433e417948607a7d58da7621fe1ca5ac3c430b82cde1e15be85a1bfd2e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
